---
title: "Tapped In: Pfizer to Acquire Metsera"
description: Pharmaceutical titan Pfizer to acquire obesity biotechnology company Metsera in a deal valued at approximately $7.3 billion.
---

[Blog | Stony Hill Advisors ](https://www.stonyhilladvisors.com/stonyhilladvisors-blog)

# [Tapped In: Pfizer to Acquire Metsera](https://www.stonyhilladvisors.com/stonyhilladvisors-blog/tapped-in-pfizer-to-acquire-metsera)

 Written by [Admin](https://www.stonyhilladvisors.com/stonyhilladvisors-blog/author/admin) | Nov 6, 2025 2:00:02 PM

Pharmaceutical titan Pfizer to acquire obesity biotechnology company Metsera in a deal valued at approximately $7.3 billion. Pfizer announced it would pay $4.9 billion, and potentially more, for its catalog of weight loss medications. They will pay $47.50 per Metsera share, with the chance for shareholders to receive up to $422.50 more per share. 

 

## **Reasons for Acquisition**

 

- **GLP-1 Technology: **With the release of GLP-1 treatments like Ozempic and Wegovy, pharmaceutical companies are joining in on the obesity drug sector. Metsera is the owner of an injectable GLP-1 stimulating agent that only needs to be administered monthly, rather than weekly, making it a desirable product.

- **Incretin & Amylin Programs: **Along with Metsera’s GLP-1 technology, they have multiple treatments and programs for weight loss. Their treatment MET-233i mimics the gut hormone amylin to suppress appetite, control glycemic levels, and slow gastric emptying.

- **Re-Entry to the Obesity Drug Sector: **Pfizer, a company you’ve no doubt heard of due to their quick response during the COVID-19 pandemic, has been behind the obesity drug boom ushered in by Ozempic. While they had their own oral GLP-1 receptor agonist to encourage weight loss, Pfizer discontinued its development due to safety issues. This acquisition re-enters them into the obesity drug sector with a portfolio of valuable weight loss drugs.

 

## **Conclusion**

 

Pfizer’s acquisition of Metsera comes down to one thing: relevance in an ever-changing market. Pfizer hasn’t kept up with the evolution of GLP-1, incretin, or amylin treatments. This acquisition catapults them into the obesity drug sector through the addition of new technology without the need to develop it themselves. 

 

Are you interested in making a move like Pfizer? [Contact Stony Hill Advisors](https://www.stonyhilladvisors.com/contact-us) today to speak to an experienced M&A advisor.

[View full post](https://www.stonyhilladvisors.com/stonyhilladvisors-blog/tapped-in-pfizer-to-acquire-metsera)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Admin"
  },
  "dateModified" : "2025-11-06T14:00:02.363Z",
  "datePublished" : "2025-11-06T14:00:02Z",
  "headline" : "Tapped In: Pfizer to Acquire Metsera",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1260,
    "url" : "https://44760.fs1.hubspotusercontent-na1.net/hubfs/44760/29.png",
    "width" : 2240
  },
  "mainEntityOfPage" : "https://www.stonyhilladvisors.com/stonyhilladvisors-blog/tapped-in-pfizer-to-acquire-metsera",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Blog "
  }
}
```